Jan 18, 2004
We are an organization funding health care programs in the developing world, and we have recently approved funding for a program to prevent transmission of HIV/AIDS from infected mothers to their newborns. I recently heard that there is evidence to suggest that the use of nevirapine in such a program involves risks to the health of the mother and also causes extended immunity to antiretroviral drugs. We are uncertain if we should proceed with funding this program or under what conditions. Can you help us with information/research findings that are most recent? We were initially excited about this program because we understood that it can significantly reduce the incidence of transmission.
Response from Dr. Sullivan
Nevirapine is still the standard of care in many parts of the world; you should consult the WHO website for detailed information on the use of nevirapine for the prevention of MTCT;http://www.who.int/3by5/publications/documents/pmtct/en/; JLS.
seroconverted when pregnant
P regnancy and Sustiva
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.